Navigation Links
New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline

RIDGEFIELD, Conn., May 8, 2012 /PRNewswire/ -- Boehringer Ingelheim will present the latest data from its respiratory research pipeline at the Annual International Conference of the American Thoracic Society (ATS 2012), in San Francisco, CA, May 18 - 23. The 14 abstracts include results from a dose-ranging study evaluating tiotropium in subjects with moderate persistent asthma, additional analyses of data from the Phase II TOMORROW trial (To Improve Pulmonary Fibrosis with BIBF 1120), and results from a Phase II trial on the long-acting b2-agonist olodaterol in patients with COPD.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, The Boehringer Ingelheim data will remain under embargo until the date and time that the data are presented (see details below). The ATS International Conference is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world, with 13 thousand attendees from 95 countries last year.

Collectively, these data underscore the company's focus on finding answers to the challenges faced by patients living with lung disease.

Title Lead Author Presentation details Dose-Ranging Study Of

Tiotropium As Treatment

For Moderate Persistent

Asthma In Adolescents

C. Vogelberg

Scientific Abstract # 305


Date: Tuesday, May 22

Time: 8:15 a.m. – 10:45 a.m.

PDT / 11:15 a.m. – 1:45 p.m.

EDTBIBF 1120Title Lead Author Presentation details Treatment Of IPF With The

Tyrosine Kinase Inhibitor

BIBF 1120: Patient-

Reported Outcomes


K.K. Brown

Oral Presentation


Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:45 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:45 p.m.) EDTEfficacy of the Tyrosine

Kinase Inhibitor BIBF 1120

in Patients with IPF:

Consistent Pattern of

Primary Endpoint Results

in Sensitivity Analyses of

the TOMORROW trial

L. Richeldi

Oral Presentation


Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:30 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:30 p.m.) EDTOlodaterolTitleLead Author Presentation details Comparison Of 24-Hour

FEV1 Profile For Once-

Daily Versus Twice-Daily

Treatment With

Olodaterol, A Novel Long-

Acting b2-Agonist, In

Patients With COPD

G. Joos

Thematic Poster # D60


Date: Monday, May 21

Time: 10:45 a.m – 12:30 p.m.

PDT / 1:45 p.m. – 3:30 p.m.

EDTLung FunctionTitleLead Author Presentation details Lung Function And

Exercise Impairment In

Patients With GOLD Stage


D. E. O'Donnell

Thematic Poster  # G74


Date: Wednesday, May 23

Time: 8:15 a.m. – 4:30 p.m.

PDT / 11:15 a.m. – 7:30 p.m. EDT

Poster Discussion from

10:45 a.m. – 12:30 p.m. PDT /

1:45 p.m. – 3:30 p.m. EDTBoehringer Ingelheim: Leading respiratory forwardTreatment of respiratory diseases has been a major area of focus for Boehringer Ingelheim for more than 90 years and significant resources are dedicated to research in this field. In addition to new possible treatment options for COPD, Boehringer Ingelheim has also branched out into developing treatment options for other airway diseases, including asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit and follow us on Twitter at


SOURCE Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):